Zobrazeno 1 - 10
of 439
pro vyhledávání: '"Young Hyuck Im"'
Autor:
Ji-Yeon Kim, Kyunghee Park, Woong-Yang Park, Jin Seok Ahn, Young-Hyuck Im, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jonghan Yu, Yeon Hee Park
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Genomic analysis of structural variants(SVs) in breast cancer (BC) patients has been conducted, but the relationship between genomic alterations and BC prognosis remains unclear. We performed RNA sequencing of 297 early BC fresh-frozen tissu
Externí odkaz:
https://doaj.org/article/8da5c32858644291988200f623ec5425
Autor:
Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
Publikováno v:
Radiation Oncology, Vol 18, Iss 1, Pp 1-10 (2023)
Abstract Aim Patients with locoregionally uncontrolled breast tumors are frequently referred for breast palliative radiotherapy (PRT) to mitigate symptoms. We analyzed the outcomes following breast PRT to optimize PRT according to risk groups. Method
Externí odkaz:
https://doaj.org/article/9976404bbafc405899dd33db240c0c03
Autor:
Jessica W. Chen, William Jacot, Javier Cortés, Ian E. Krop, Susan Dent, Nadia Harbeck, Michelino De Laurentiis, Véronique Diéras, Young‐Hyuck Im, Thomas J. Stout, Frauke Schimmoller, Heidi M. Savage, Katherine E. Hutchinson, Timothy R. Wilson
Publikováno v:
Molecular Oncology, Vol 17, Iss 10, Pp 2000-2016 (2023)
Taselisib is a potent β‐sparing phosphatidylinositol 3‐kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha (PIK3CA)‐mutated (PIK3CAmut) advance
Externí odkaz:
https://doaj.org/article/535a6a7921404a8298c1f95b55637007
Autor:
Ji-Yeon Kim, Sabin Park, Eun Yoon Cho, Jeong Eon Lee, Hae Hyun Jung, Byung Joo Chae, Seok Won Kim, Seok Jin Nam, Soo Youn Cho, Yeon Hee Park, Jin Seok Ahn, Semin Lee, Young-Hyuck Im
Publikováno v:
Experimental and Molecular Medicine, Vol 55, Iss 7, Pp 1451-1461 (2023)
Abstract Apocrine carcinoma is a rare breast cancer subtype. As such, the genomic characteristics of apocrine carcinoma with triple negative immunohistochemical results (TNAC), which has been treated as triple negative breast cancer (TNBC), have not
Externí odkaz:
https://doaj.org/article/d8897389d2f94b6bbb0403cf5292d380
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12438-12451 (2023)
Abstract Background TP53 is the most commonly mutated gene across all cancer types. R175H mutation was considered structural mutation where the mutation causes misfolding of the protein and leads to a significant conformational alterations within p53
Externí odkaz:
https://doaj.org/article/8c44056f1eff4fa99292bf8f7bda024c
Autor:
Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim
Publikováno v:
Breast, Vol 72, Iss , Pp 103594- (2023)
Aim: The role of regional nodal irradiation (RNI) after preoperative systemic treatment (PST) with targeted therapy for HER2-positive breast cancer remains uncertain. This study aimed to investigate the impact of RNI on locoregional recurrence (LRR)
Externí odkaz:
https://doaj.org/article/97a1e0350e3a4a21ab7dfbec2c148114
Autor:
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young‐Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling‐Ming Tseng, Mei‐Ching Liu, Begoña Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de laHaba‐Rodriguez, Do‐Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue
Publikováno v:
Molecular Oncology, Vol 16, Iss 12, Pp 2355-2366 (2022)
As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salv
Externí odkaz:
https://doaj.org/article/04d4128992ee4c3590607960b247f2b8
Autor:
Ji-Yeon Kim, Jeehyun Kim, Eun Yoon Cho, Yeon Hee Park, Jin Seok Ahn, Kyoung-Mee Kim, Young-Hyuck Im
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionImmune checkpoint inhibitor (ICI) is one of the standard treatment strategies in triple negative breast cancer (TNBC). However, the benefit of ICI with chemotherapy is limited in metastatic TNBC. In this study, we evaluated the effect of
Externí odkaz:
https://doaj.org/article/25f16b17854a49a683f704665485cc99
Autor:
Hae Hyun Jung, Ji-Yeon Kim, Eun Yoon Cho, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 21, p 15576 (2023)
Neoadjuvant chemotherapy (NAC) is widely used as a standard treatment for early-stage triple-negative breast cancer (TNBC). While patients who achieve pathologic complete response (pCR) have a highly favorable outcome, patients who do not achieve pCR
Externí odkaz:
https://doaj.org/article/8cfde21e7d99445d92c285af68ad9a7f
Autor:
Sunghoon Joo, Eun Sook Ko, Soonhwan Kwon, Eunjoo Jeon, Hyungsik Jung, Ji-Yeon Kim, Myung Jin Chung, Young-Hyuck Im
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract The achievement of the pathologic complete response (pCR) has been considered a metric for the success of neoadjuvant chemotherapy (NAC) and a powerful surrogate indicator of the risk of recurrence and long-term survival. This study aimed to
Externí odkaz:
https://doaj.org/article/89bbfdeddf364266aeeb4cea1e90b29a